Physician profile
Mayanka Singh
NPI 1154705697
$738.58
in general payments reported to CMS, 2019-2025
12 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $90.18 · 2022: $33.89 · 2023: $179 · 2024: $120 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $195.40 | 2023-2025 | Cabenuva, Rukobia, Apretude |
| Allergan, INC. | $120.77 | 2019 | |
| Gilead Sciences, INC. | $102.52 | 2023-2025 | Veklury |
| Pfizer INC. | $90.18 | 2020 | |
| Insmed, INC. | $66.32 | 2025 | Brinsupri, Arikayce |
| Abbvie INC. | $42.95 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $28.72 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Shionogi INC | $22.26 | 2023 | Fetroja |
| Janssen Biotech, INC. | $21.79 | 2022 | |
| Napo Pharmaceuticals INC | $18.22 | 2023 | Mytesi |
| Electromed, INC. | $16.31 | 2023 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayanka Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.